Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF with Interferon-Alpha for CML
NCT00003561Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 1998
- Primary completion
- Oct 2001
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim in chronic myeloid leukemia (CML), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Feb 1998; status: terminated.
02
Drugs
sargramostim
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00003561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003561.